Academy’s Monthly Bulletin: June 2024
Academy's Monthly Bulletin: June 2024
A Monthly Newsletter Dedicated to Our Academy Membership Community!
Here is the summary of our posted Lectures, YouTube videos & Updates for June 2024:
- Austedo XR: FDA Approved for Tardive Dyskinesia.
- Comparing VMAT-2 Inhibitors for Tardive Dyskinesia.
- Navigating the Complex Terrain of Drug Interactions: Hydroxychloroquine & Psychiatric Medications.
- FDA Approves Clonidine XR: First Liquid Non-Stimulant for ADHD.
- Postpartum Onset OCD.
- Comparing Antipsychotics for their Risk of Pneumonia.
(1) Austedo XR: FDA Approved for Tardive Dyskinesia
In a significant advancement for those suffering from tardive dyskinesia (TD), the U.S. Food and Drug Administration (FDA) recently approved Austedo XR (extended-release deutetrabenazine). This approval brings a new, convenient treatment option for patients grappling with this often debilitating condition.
The most notable advantage of Austedo XR is its once-daily dosing regimen. This is a significant improvement over the immediate-release form, which requires twice-daily dosing. A once-daily pill is easier for patients to adhere to, improving overall treatment compliance.
Watch our YouTube video on how to dose this medication:
(2) Comparing VMAT-2 Inhibitors for Tardive Dyskinesia
In this session. Dr. Harvinder Singh will compare VMAT-2 inhibitors (Tetrabenazine, Deutetrabenazine and Valbenazine) in the following sections:
- Dosing & Strengths: Which one is most and least favorable in terms of dosing, titration and amount of pills needed per day?
- How to Dose & Titrate each VMAT-2 inhibitor?
- Comparing use of each medication in special population.
- Comparing Contraindications.
- Understanding the role of genotyping: Drug interactions & CYP450.
- Comparing common side effects.
Here is one slide from this presentation on
“How to Dose each VMAT-2 Inhibitor for TD management”
(3) Navigating the Complex Terrain of Drug Interactions: Hydroxychloroquine & Psychiatric Medications
In the realm of modern medicine, managing drug interactions is crucial for ensuring patient safety and efficacy of treatments. Among these interactions, those between hydroxychloroquine and psychiatric medications present unique challenges and considerations. As hydroxychloroquine is used for conditions like rheumatoid arthritis, lupus, and malaria prevention, understanding its interactions with psychiatric drugs is essential for clinicians and patients alike.
(4) FDA Approves Clonidine XR: First Liquid Non-Stimulant for ADHD
Dr. Harvinder Singh has summarized Clonidine XR (Onyda XR) in the following sections:
(1) FDA Indication
(2) Mechanism of Action
(3) Clonidine vs Guanfacine
(4) Understanding Dosing & Titration
(5) How to Discontinue?
(6) Specific Administration Instructions
(7) Switching from IR to XR formulation
(8) Warnings & Precautions
(9) Important Drug Interactions
(5) Postpartum Onset OCD
Dr. Mary Kimmel is the medical director of NC Maternal Mental Health MATTERS program & Co-Director of UNC’s Perinatal Psychiatry Program. She has discussed this clinically relevant topic in the following sections:
- Case examples: (a) “Normal” mom worries, (b) Postpartum OCD, or (c) Postpartum psychosis.
- Underlying Biology and Neuroanatomy involved in postpartum onset OCD
- Postpartum mood symptoms & 5 symptoms dimensions of obsessions and compulsions in the postpartum period.
- Differentiating (a) OCD and postpartum depression; (b) OCD and postpartum Psychosis.
- Risk assessment of harm to the baby.
- Postpartum OCD in fathers.
- Treatment algorithm of (a) Postpartum OCD; (b) Postpartum Psychosis.
(6) Comparing Antipsychotics for their Risk of Pneumonia
Antipsychotic medications are critical in managing schizophrenia and other related disorders, but they come with various side effects, one of which is the increased risk of pneumonia. A comprehensive study published in JAMA Psychiatry in June 2024 offers valuable insights into the comparative pneumonia risks associated with different antipsychotic medications. Let’s delve into the key findings and their implications for clinical practice.
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2024 All Rights Reserved.
